The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib.
J. F. Hilton
No relevant relationships to disclose
L. Seymour
No relevant relationships to disclose
A. Le Maitre
No relevant relationships to disclose
D. Tu
No relevant relationships to disclose
F. A. Shepherd
Consultant or Advisory Role - OSI Pharmaceuticals; Roche
P. A. Bradbury
No relevant relationships to disclose